• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床试验设计和建议:我们可以共同接受它们。

Clinical trial design and recommendations: collectively, we can take them.

机构信息

, Napa, CA, 94559, USA.

出版信息

Clin Exp Med. 2018 May;18(2):291-295. doi: 10.1007/s10238-017-0476-z. Epub 2017 Oct 13.

DOI:10.1007/s10238-017-0476-z
PMID:29030728
Abstract

There is dynamic opportunity to advance medical research and clinical trial innovation in the USA and throughout the world. Identified problems and solutions in the clinical research and clinical trial enterprise have emerged over recent years. Strategic plans, public reports, expertise panels and international agreements have been produced, and now is the time to move forward collectively. Recommendations should be reviewed, especially because global healthcare can take them. A robust and future medical research enterprise hinges on maximized clinical trial efficiency, both in the USA and abroad.

摘要

在美国乃至全世界,推进医学研究和临床试验创新的机会层出不穷。近年来,临床研究和临床试验领域出现了一些问题和解决方案。已经制定了战略计划、公开报告、专家小组和国际协议,现在是共同向前推进的时候了。建议应得到审查,特别是因为全球医疗保健可以借鉴这些建议。一个强大的未来医学研究企业取决于临床试验效率的最大化,无论是在美国还是在国外。

相似文献

1
Clinical trial design and recommendations: collectively, we can take them.临床试验设计和建议:我们可以共同接受它们。
Clin Exp Med. 2018 May;18(2):291-295. doi: 10.1007/s10238-017-0476-z. Epub 2017 Oct 13.
2
Assessing cognitive function in bipolar disorder: challenges and recommendations for clinical trial design.评估双相情感障碍中的认知功能:临床试验设计的挑战与建议
J Clin Psychiatry. 2015 Mar;76(3):e342-50. doi: 10.4088/JCP.14cs09399.
3
American Society of Clinical Oncology policy statement: oversight of clinical research.美国临床肿瘤学会政策声明:临床研究监督
J Clin Oncol. 2003 Jun 15;21(12):2377-86. doi: 10.1200/JCO.2003.04.026. Epub 2003 Apr 29.
4
Critical Care Network in the State of Qatar.卡塔尔国重症监护网络。
Qatar Med J. 2019 Nov 7;2019(2):2. doi: 10.5339/qmj.2019.qccc.2. eCollection 2019.
5
Recommendations for the design of small population clinical trials.小人群临床试验设计建议。
Orphanet J Rare Dis. 2018 Nov 6;13(1):195. doi: 10.1186/s13023-018-0931-2.
6
Lack of compliance of European Public Assessment Reports to guidelines for paediatric drug development before the introduction of paediatric investigation plans.在引入儿科研究计划之前,欧洲公共评估报告在儿科药物开发指南方面的不遵守情况。
Clin Trials. 2013 Apr;10(2):269-79. doi: 10.1177/1740774512470220. Epub 2013 Jan 18.
7
A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors.一项关于医学院校与行业赞助商之间临床试验协议条款的全国性调查。
N Engl J Med. 2002 Oct 24;347(17):1335-41. doi: 10.1056/NEJMsa020349.
8
Design and conduct of clinical trials: report of the Clinical Trials Subcommittee of the International Dry Eye WorkShop (2007).
Ocul Surf. 2007 Apr;5(2):153-62. doi: 10.1016/s1542-0124(12)70084-8.
9
A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial.罕见病临床试验清单:障碍与前瞻性行动——从杜氏肌营养不良症(FOR-DMD)试验中汲取的经验教训
Trials. 2018 May 10;19(1):291. doi: 10.1186/s13063-018-2645-0.
10
Researchers' views of the acceptability of restrictive provisions in clinical trial agreements with industry sponsors.研究人员对与行业赞助商签订的临床试验协议中限制性条款可接受性的看法。
Account Res. 2005 Jul-Sep;12(3):163-91. doi: 10.1080/08989620500216380.

本文引用的文献

1
Interventions to reduce corruption in the health sector.减少卫生部门腐败现象的干预措施。
Cochrane Database Syst Rev. 2016 Aug 16;2016(8):CD008856. doi: 10.1002/14651858.CD008856.pub2.
2
A New Ethical Challenge for Institutional Review Boards (IRBs)/Ethics Committees (ECs) in the Assessment of Pediatric Clinical Trials.机构审查委员会(IRB)/伦理委员会(EC)在评估儿科临床试验中面临的新伦理挑战。
Children (Basel). 2015 May 28;2(2):198-210. doi: 10.3390/children2020198.
3
Availability and affordability of new medicines in Latin American countries where pivotal clinical trials were conducted.
开展关键临床试验的拉丁美洲国家新药物的可及性和可负担性。
Bull World Health Organ. 2015 Oct 1;93(10):674-683. doi: 10.2471/BLT.14.151290. Epub 2015 Jul 29.
4
Improving Clinical Trial Efficiency: Thinking outside the Box.提高临床试验效率:跳出框框思考。
Am Soc Clin Oncol Educ Book. 2015:e141-7. doi: 10.14694/EdBook_AM.2015.35.e141.
5
A generation at risk: young investigators and the future of the biomedical workforce.一代人处于危险之中:年轻的研究人员和生物医学劳动力的未来。
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):313-8. doi: 10.1073/pnas.1418761112. Epub 2015 Jan 5.
6
The Clinical Trials Transformation Initiative: innovation through collaboration.临床试验转化倡议:通过合作实现创新。
Nat Rev Drug Discov. 2014 Nov;13(11):797-8. doi: 10.1038/nrd4442.
7
Use of crowdsourcing for cancer clinical trial development.利用众包进行癌症临床试验开发。
J Natl Cancer Inst. 2014 Sep 12;106(10). doi: 10.1093/jnci/dju258. Print 2014 Oct.
8
Site-specific predictors of successful recruitment to a perinatal clinical trial.围产期临床试验成功招募的特定地点预测因素。
Clin Trials. 2014 Oct;11(5):584-9. doi: 10.1177/1740774514543539. Epub 2014 Jul 23.
9
Sharing clinical trial data on patient level: opportunities and challenges.在患者层面分享临床试验数据:机遇与挑战。
Biom J. 2015 Jan;57(1):8-26. doi: 10.1002/bimj.201300283. Epub 2014 Jun 18.
10
Ethical pharmaceutical promotion and communications worldwide: codes and regulations.全球范围内的药品合理推广与沟通:法规与准则
Philos Ethics Humanit Med. 2014 Mar 29;9:7. doi: 10.1186/1747-5341-9-7.